Edinburgh, UK-based Caldan Therapeutics has appointed Dr Mark Payton as chief executive officer.
Dr Payton joins the metabolic disease specialist – a spin-out company from the Universities of Glasgow and Southern Denmark – from MAPBiotech, where he has served as chief executive officer since 2014.
Prior to this, Dr Payton has been chief executive officer of both Atopix Therapeutics and Oxagen, both based in Oxfordshire, UK, and brings further industry experience from GlaxoSmithKline and Biogen.
He co-founded autoimmune disease-focused Orca Pharmaceuticals in 2012, and currently also serves as a senior advisor to The Harrington Project for Discovery and Development.
Dr Liz Roper, partner at Epidarex Capital, which backs Caldan Therapeutics, said: “We are delighted to welcome Mark on board to lead Caldan Therapeutics moving forward.
“Continuing to build a strong management team with experienced and talented executives is crucial to building on the science of Professors Milligan and Ulven to deliver new drugs for metabolic diseases.”